Amphastar Pharmaceuticals (AMPH) Income towards Parent Company (2013 - 2026)

Amphastar Pharmaceuticals' Income towards Parent Company history runs 14 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 74.61% year-over-year to $6.4 million in Q1 2026; TTM through Mar 2026 was $102.4 million, a 27.71% decrease from a year earlier, with the FY2025 full-year figure at $121.2 million, down 24.26% from the prior year.
• Income towards Parent Company retreated to $6.4 million in Q1 2026 per AMPH's latest filing, from $47.6 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $49.6 million in Q3 2023 and bottomed at -$145.2 million in Q4 2023.
• The 5-year median for Income towards Parent Company is $26.8 million (2023), against an average of $19.9 million.
• Across the five-year window, Income towards Parent Company surged 530.36% in 2022 and slumped 527.58% in 2023, its largest moves.
• Year by year, Income towards Parent Company stood at $34.0 million in 2022, then slumped by 527.58% to -$145.2 million in 2023, then soared by 126.14% to $38.0 million in 2024, then grew by 25.34% to $47.6 million in 2025, then slumped by 86.51% to $6.4 million in 2026.
• Per Business Quant, the three latest AMPH Income towards Parent Company figures stand at $6.4 million (Q1 2026), $47.6 million (Q4 2025), and $17.3 million (Q3 2025).